Zymeworks (ZYME) shares slumped 46% pre-bell Tuesday, adding to Monday's losses.
Arvinas (ARVN) shares retreated 41% after the company and Pfizer (PFE) said their phase 3 trial of vepdegestrant for the treatment of breast cancer failed to reach statistical significance in improvement in progression free survival in the intent-to-treat population.
Evolus (EOLS) shares fell 36% after Monday's 6.6% loss.
Stoke Therapeutics (STOK) shares decreased 36% following a muted session.
Medallion Financial (MFIN) shares were down 32% after a 2.4% gain in the previous session.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。